Literature DB >> 23955451

Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers.

Hiroko Ikeda1, Kenichi Harada, Yasunori Sato, Motoko Sasaki, Norihide Yoneda, Seiko Kitamura, Yoshiko Sudo, Akishi Ooi, Yasuni Nakanuma.   

Abstract

OBJECTIVES: To examine the clinicopathologic features of combined hepatocellular-cholangiocarcinoma (HC-CC), which the World Health Organization (WHO) proposed classifying into 2 types, and the expression of delta-like 1 homolog (DLK1), as well as putative stem cell markers, such as NCAM/CD56 and CD133.
METHODS: In this study we examined the expression of stem cell markers using immunohistochemistry.
RESULTS: Thirty-six cases of combined HC-CC were subclassified into 24 cases, with more than 5% stem cell features (group B) and 12 cases with less than 5% stem cell areas (group A). The postoperative overall survival rate was worse for group B than for group A. DLK1 was frequently expressed in group B cases compared with group A, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma cases.
CONCLUSIONS: The 2010 WHO classification seems important for elucidating the pathogenesis of stem cell-related liver cancers.

Entities:  

Keywords:  Combined hepatocellular-cholangiocarcinoma; DLK1; Hepatoblast; NCAM/CD56; Stem cells

Mesh:

Substances:

Year:  2013        PMID: 23955451     DOI: 10.1309/AJCP66AVBANVNTQJ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  19 in total

Review 1.  Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.

Authors:  Elizabeth M Brunt; Valerie Paradis; Christine Sempoux; Neil D Theise
Journal:  Hepat Oncol       Date:  2015-07-28

2.  cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Authors:  Elizabeth Brunt; Shinichi Aishima; Pierre-Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W M S Tsui; Xin-Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

3.  Post-resection Prognosis of Combined Hepatocellular Carcinoma-Cholangiocarcinoma According to the 2010 WHO Classification.

Authors:  Dong-Hwan Jung; Shin Hwang; Seung-Mo Hong; Yong-Kyu Chung; Gi-Won Song; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gil-Chun Park; Han Chu Lee; Young-Suk Lim; Eun Sil Yu; Sung-Gyu Lee
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

4.  Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Young-In Yoon; Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Jong-Woo Lee; Seung-Mo Hong; Eun Sil Yu; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-12-01       Impact factor: 3.452

Review 5.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

6.  Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma.

Authors:  Meng Wang; Jiansheng Li; Liping Wang; Xinfeng Chen; Zhen Zhang; Dongli Yue; Yu Ping; Xiaojuan Shi; Lan Huang; Tengfei Zhang; Li Yang; Yongfu Zhao; Xiuxian Ma; Dexu Li; Zhengjun Fan; Longshuan Zhao; Zhe Tang; Wenlong Zhai; Bin Zhang; Yi Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 7.  Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review.

Authors:  Damiano Gentile; Matteo Donadon; Ana Lleo; Alessio Aghemo; Massimo Roncalli; Luca di Tommaso; Guido Torzilli
Journal:  Liver Cancer       Date:  2019-11-01       Impact factor: 11.740

Review 8.  Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.

Authors:  An-Qiang Wang; Yong-Chang Zheng; Juan Du; Cheng-Pei Zhu; Han-Chun Huang; Shan-Shan Wang; Liang-Cai Wu; Xue-Shuai Wan; Hao-Hai Zhang; Ruo-Yu Miao; Xin-Ting Sang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

9.  Postresection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma according to the 2010 World Health Organization classification: single-center experience of 168 patients.

Authors:  Minjae Kim; Shin Hwang; Chul-Soo Ahn; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Gil-Chun Park; Seung-Mo Hong
Journal:  Ann Surg Treat Res       Date:  2021-04-29       Impact factor: 1.859

Review 10.  Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma.

Authors:  Maurizio Romano; Francesco De Francesco; Giuseppe Pirozzi; Enrico Gringeri; Riccardo Boetto; Marina Di Domenico; Barbara Zavan; Giuseppe A Ferraro; Umberto Cillo
Journal:  Oncoscience       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.